{
  "variant": {
    "gene": "SNCA",
    "protein_change": "E46K",
    "variant_string_id": "SNCA_E46K"
  },
  "functional_evidence": {
    "assay_type": "Phospholipid binding and filament assembly assays",
    "results": {
      "phospholipid_binding": "Increased compared to wild-type",
      "filament_assembly": "Similar to A53T mutation (pathogenic), but increased compared to A30P (pathogenic)",
      "filament_morphology": "Twisted filaments with specific cross-over spacing"
    },
    "comparison_to_known_mutations": {
      "A30P": "Known pathogenic mutation",
      "A53T": "Known pathogenic mutation with similar filament assembly rates"
    }
  },
  "acmg_flowchart_evaluation": {
    "step_1": {
      "disease_mechanism_defined": true,
      "description": "E46K is associated with dementia with Lewy bodies and Parkinson's disease, with functional assays (phospholipid binding and filament assembly) relevant to disease pathology (Lewy bodies)."
    },
    "step_2": {
      "assay_applicability": true,
      "description": "Phospholipid binding and filament assembly assays are standard in alpha-synuclein research and directly relate to the role of SNCA in Lewy body formation."
    },
    "step_3": {
      "sub_step_3a": {
        "basic_controls_replicates": false,
        "description": "The abstract does not explicitly mention experimental controls or replicates."
      },
      "sub_step_3b": {
        "assay_validity": true,
        "description": "Phospholipid binding and filament assembly assays are broadly accepted and validated in the field of neurodegenerative disease research."
      },
      "sub_step_3c": {
        "variant_controls_used": true,
        "description": "The study compares E46K to known pathogenic mutations (A30P, A53T), which are widely recognized as pathogenic in Parkinson's disease."
      }
    },
    "step_4": {
      "sub_step_4a": {
        "statistical_analysis": false,
        "description": "The abstract does not report OddsPath or statistical metrics (e.g., p-values, confidence intervals)."
      },
      "sub_step_4b": {
        "number_of_controls": "At least 11 (comparison to A30P, A53T, and other variants)",
        "description": "The study includes known pathogenic variants (A30P, A53T) as controls, implying sufficient statistical power for interpretation."
      },
      "sub_step_4c": {
        "odds_path_inference": {
          "ps3": {
            "very_strong": false,
            "moderate": true,
            "supporting": false
          },
          "bs3": {
            "very_strong": false,
            "moderate": false,
            "supporting": false
          }
        },
        "description": "The comparison to known pathogenic variants (A30P, A53T) with similar filament assembly rates and increased phospholipid binding supports a moderate PS3 classification."
      }
    }
  },
  "evidence_strength": {
    "classification": "PS3_moderate",
    "justification": "The E46K mutation demonstrates increased phospholipid binding and filament assembly comparable to known pathogenic variants (A30P, A53T), with assays validated in the field. The study includes sufficient variant controls (A30P, A53T) and implies statistical significance through functional comparison, meeting criteria for PS3_moderate."
  }
}